Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Journal of Cellular Physiology

• Publication date

  1992-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/jcp.1041500126PMID 1370503
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii

  2007cited by this paper
• Fibroblast growth factor receptor levels decrease during chick embryogenesis

  1990cited by this paper
• Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan

  1989cited by this paper
• Biological and binding studies of acidic fibroblast growth factor in the presence of substituted dextran.

  1989cited by this paper
• The heparin-binding (fibroblast) growth factor family of proteins.

  1989cited by this paper
• Heparin‐derived oligosaccharides: Affinity for acidic fibroblast growth factor and effect on its growth‐promoting activity for human endothelial cells

  1989cited by this paper
• Stabilization by heparin of acidic fibroblast growth factor mitogenicity for human endothelial cells in vitro

  1989cited by this paper
• Importance of size, sulfation, and anticoagulant activity in the potentiation of acidic fibroblast growth factor by heparin.

  1989cited by this paper
• Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine capillary endothelial cells

  1988cited by this paper
• Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation

  1988cited by this paper
• Heparin protects heparin-binding growth factor-I from proteolytic inactivation in vitro.

  1988cited by this paper
• Effects of aFGF and bFGF on wound healing in rabbit corneas.

  1987cited by this paper
• Angiogenic factors.

  1987cited by this paper
• Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response.

  1987cited by this paper
• Aortic endothelial cells synthesize basic fibroblast growth factor which remains cell associated and platelet‐derived growth factor‐like protein which is secreted

  1987cited by this paper
• Biochemical comparative studies between eye- and brain-derived growth factors.

  1987cited by this paper
• Heparin protects basic and acidic FGF from inactivation

  1986cited by this paper
• Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells.

  1986cited by this paper
• Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF.

  1985cited by this paper
• Brain-derived acidic fibroblast growth factor: complete amino acid sequence and homologies.

  1985cited by this paper
• Effect of heparin on vascular smooth muscle cells. I. Cell metabolism

  1985cited by this paper
• Anticomplementary activity of dextran derivatives.

  1985cited by this paper
• Heparin affinity of anionic and cationic capillary endothelial cell growth factors: analysis of hypothalamus-derived growth factors and fibroblast growth factors.

  1985cited by this paper
• Interaction of endothelial cell growth factor with heparin: characterization by receptor and antibody recognition.

  1985cited by this paper
• Correction. Purification of the Messenger RNA Cap-Binding Protein Using a New Affinity Medium

  1984cited by this paper
• Purification of two distinct growth factors from bovine neural tissue by heparin affinity chromatography.

  1984cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Protective Effects of a synthetic glycosaminoglycan mimetic (OTR4132) in a rat immunotoxic lesion model of septohippocampal cholinergic degeneration

  2022cites this paper
• The Potential of FGF-2 in Craniofacial Bone Tissue Engineering: A Review

  2021cites this paper
• Dextran Sulfate-amplified Extracellular Matrix Deposition Promotes Osteogenic Differentiation of Mesenchymal Stem Cells.

  2021cites this paper
• Targeting Biological Polyanions in Blood: Strategies towards the Design of Therapeutics.

  2020cites this paper
• Fibroblast Growth Factor 2—A Review of Stabilisation Approaches for Clinical Applications

  2020cites this paper
• Evaluation of corneal epithelial wound healing after penetrating keratoplasty in patients receiving a new matrix therapy agent (regenerating agent)

  2018cites this paper
• Periodontal reconstruction by heparan sulfate mimetic-based matrix therapy in Porphyromonas gingivalis-infected mice

  2018cites this paper
• Smart Polymers: Medicine and Biotechnology Applications

  2017cites this paper
• RGTA®-based matrix therapy - A new branch of regenerative medicine in locomotion.

  2017cites this paper
• Matrix therapy has new branch of regenerative medicine and its applications in burned treatment : From fundamental to clinic

  2017cites this paper
• A Heparin-Mimicking Block Copolymer Both Stabilizes and Increases the Activity of Fibroblast Growth Factor 2 (FGF2)

  2016cites this paper
• RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

  2016cites this paper
• Blood compatibility of heparin-inspired, lactose containing, polyureas depends on the chemistry of the polymer backbone

  2016cites this paper
• Heparin-Mimicking Polymers: Synthesis and Biological Applications

  2016cites this paper
• Mussel-inspired coatings on Ag nanoparticle-conjugated carbon nanotubes: bactericidal activity and mammal cell toxicity.

  2016cites this paper
• The development of heparin-based materials for tissue engineering applications to treat rotator cuff tendon injuries

  2014cites this paper
• Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis‐Related Disorders

  2014cites this paper
• RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies.

  2013cites this paper
• Developing drugs from sugars: current state of glycosaminoglycan-derived therapeutics

  2012cites this paper
• [Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report].

  2012cites this paper
• Heparan sulfate-based treatments for regenerative medicine.

  2011cites this paper
• Procédés de culture de cellules indifférenciées à l'aide de compositions à libération prolongée

  2011cites this paper
• Matrix Therapy with RGTA OTR4120 Improves Healing Time and Quality in Hairless Rats with Deep Second-Degree Burns

  2011cites this paper
• Inhibitors of slit protein interactions with the heparan sulphate proteoglycan glypican‐1: Potential agents for the treatment of spinal cord injury

  2010cites this paper
• FGF-1 induces ATP release from spinal astrocytes in culture and opens pannexin and connexin hemichannels

  2010cites this paper
• Heparin mimicking polymer promotes myogenic differentiation of muscle progenitor cells.

  2010cites this paper
• Extracellular matrix-derived products modulate endothelial and progenitor cell migration and proliferation in vitro and stimulate regenerative healing in vivo.

  2010cites this paper
• Heparin/heparan sulphate-based drugs.

  2010cites this paper
• Insights on a new path of pre-mitochondrial apoptosis regulation by a glycosaminoglycan mimetic

  2009cites this paper
• Enhancement of the biological activity of BMP-2 by synthetic dextran derivatives.

  2009cites this paper
• Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.

  2009cites this paper
• A Hibiscus Abelmoschus seed extract as a protective active ingredient to favour FGF‐2 activity in skin

  2009cites this paper
• Benzylaminated dextran-modified hydrogels: a long-term bioactive TGF-beta1 carrier.

  2009cites this paper
• Growth factor delivery approaches in hydrogels.

  2009cites this paper
• Enhancement of PDGF-BB mitogenic activity on human dermal fibroblasts by biospecific dextran derivatives.

  2008cites this paper
• [Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].

  2008cites this paper
• Étude pilote d’un nouvel agent de thérapie matricielle (RGTA OTR4120 ® ) dans les ulcères de cornée et les dystrophies cornéennes rebelles

  2008cites this paper
• The heparanome and regulation of cell function: structures, functions and challenges.

  2008cites this paper
• Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats

  2008cites this paper
• Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats.

  2008cites this paper
• RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin.

  2007cites this paper
• In vitro stimulation of human endothelial cells by derivatized dextrans

  2007cites this paper
• Struggle at the Site of Nerve Injury: a rat sciatic nerve study on fundamental problems of peripheral nerve injury

  2006cites this paper
• Polysaccharide Microarrays for Polysaccharide–Platelet‐Derived‐Growth‐Factor Interaction Studies

  2006cites this paper
• ROLE D'ENDOCAN DANS LA CROISSANCE TUMORALE ET EFFETS DES ANTICORPS ANTI-ENDOCAN SUR LE DEVELOPPEMENT TUMORAL

  2006cites this paper
• [Regenerating agents (RGTAs): a new therapeutic approach].

  2006cites this paper
• Dextran derivatives modulate collagen matrix organization in dermal equivalent

  2006cites this paper
• Periodontitis destructions are restored by synthetic glycosaminoglycan mimetic.

  2006cites this paper
• Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro.

  2006cites this paper
• Controlled release of fibroblast growth factor-2 from an injectable 6-O-desulfated heparin hydrogel and subsequent effect on in vivo vascularization.

  2006cites this paper
• Les agents de rgnration (ou RGTAs) : une nouvelle approche thrapeutique

  2006cites this paper
• Rétention prolongée de TGFβ1 par des hydrogels à base de dextrane fonctionnalisé : synthèse, caractérisation et évaluations biologiques

  2006cites this paper
• - 9-COMPARISON OF TWO WAYS OF ADMINISTRATION OF GROWTH FACTORS ( bFGF AND RGTA ) TO IMPROVE LATISSIMUS DORSI MUSCLE FLAP VASCULARIZATION AND TROPHICITY

  2006cites this paper
• EFFETS D'UN DEXTRAN SUBSTITUÉ SUR LA PRODUCTION DE FEUILLETS DERMIQUES ET DU GEL DE FIBRINE SUR LA QUALITÉ DES FEUILLETS D'ÉPIDERMES CULTIVÉS

  2005cites this paper
• Novel glycosaminoglycan mimetic (RGTA, RGD120) contributes to enhance skeletal muscle satellite cell fusion by increasing intracellular Ca2+ and calpain activity

  2005cites this paper
• Effect of an oversulfated exopolysaccharide on angiogenesis induced by fibroblast growth factor-2 or vascular endothelial growth factor in vitro.

  2005cites this paper
• A Synthetic Glycosaminoglycan Mimetic Binds Vascular Endothelial Growth Factor and Modulates Angiogenesis*

  2005cites this paper
• Retention of transforming growth factor beta1 using functionalized dextran-based hydrogels.

  2005cites this paper
• A glycopolymer chaperone for fibroblast growth factor-2.

  2004cites this paper
• Controlled sulfatation of natural anionic bacterial polysaccharides can yield agents with specific regenerating activity in vivo.

  2004cites this paper
• Regulation of the collagen phenotype expression of gamma-irradiated vascular smooth muscle cells by heparan mimetics (RGTA).

  2004cites this paper
• Can fibroblast growth factors substitute for bovine pituitary extracts in culture systems for hair apparatus cells?

  2004cites this paper
• An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters.

  2004cites this paper
• Effect of a dextran derivative associated with TGF-β1 or FGF-2 on dermal fibroblast behaviour in dermal equivalents

  2004cites this paper
• Kinetic Study of Early Regenerative Effects of RGTA11, a Heparan Sulfate Mimetic, in Rat Craniotomy Defects

  2004influential citation
• A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers

  2003cites this paper
• Systemic Effects on Bone Healing of a New Hyaluronic Acid-Like Bacterial Exopolysaccharide

  2003cites this paper
• Heparin‐like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G

  2003cites this paper
• RGTA modulates the healing pattern of a defect in a monolayer of osteoblastic cells by acting on both proliferation and migration.

  2003cites this paper
• Growth factors improve latissimus dorsi muscle vascularization and trophicity after cardiomyoplasty.

  2003cites this paper
• Effect of heparin and antivenom on skeletal muscle damage produced by Bothrops jararacussu venom.

  2002cites this paper
• A New Bone-Healing Material: A Hyaluronic Acid-Like Bacterial Exopolysaccharide

  2002cites this paper
• Pharmacological studies of RGTA(11), a heparan sulfate mimetic polymer, efficient on muscle regeneration.

  2002influential citation
• Interaction of specifically chemically modified dextrans with transforming growth factor beta1: potentiation of its biological activity.

  2002cites this paper
• Heparin-like polymer improved healing of gastric and colic ulceration.

  2002cites this paper
• Heparin and non-heparin-like dextrans differentially modulate endothelial cell proliferation: in vitro evaluation with soluble and crosslinked polysaccharide matrices.

  2002cites this paper
• Growth inhibition of human melanoma tumor cells by the combination of sodium phenylacetate (NaPA) and substituted dextrans and one NaPA–dextran conjugate

  2002cites this paper
• Glycosaminoglycan-mimetic biomaterials. 3. Glycopolymers prepared from alkene-derivatized mono- and disaccharide-based glycomonomers.

  2002cites this paper
• Beneficial use of fibroblast growth factor 2 and RGTA, a new family of heparan mimics, for endothelialization of PET prostheses.

  2001cites this paper
• Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factor-beta1.

  2001cites this paper
• Heparan sulfate mimetics modulate calpain activity during rat Soleus muscle regeneration

  2001cites this paper
• Human Plasmin Enzymatic Activity Is Inhibited by Chemically Modified Dextrans*

  2000cites this paper
• New agents for the treatment of infarcted myocardium

  2000influential citation
• Synthesis of sulfated colominic acids and their interaction with fibroblast growth factors.

  2000cites this paper
• [Effect of carrageenan and indomethacin on the growth of a murine fibrosarcoma].

  2000cites this paper
• Toward New Biomaterials

  2000cites this paper
• EFECTO DE LA CARRAGENINA E INDOMETACINA SOBRE EL CRECIMIENTO DE UN FIBROSARCOMA MURINO

  2000cites this paper
• Blood-Compatible Bioactive Polymers

  2000cites this paper
• Effects of the binding of a dextran derivative on fibroblast growth factor 2: secondary structure and receptor-binding studies.

  1999cites this paper
• A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle

  1999cites this paper
• The effect of pentosan polysulphate on bone healing of rat cranial defects.

  1999cites this paper
• Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression.

  1999cites this paper
• Kohlenhydratmimetika: ein neuer Lösungsansatz für das Problem der kohlenhydratvermittelten biologischen Erkennung

  1999cites this paper
• Low-molecular-weight dextran derivatives (f-CMDB) enter the nucleus and are better cell-growth inhibitors compared with parent CMDB polymers.

  1999cites this paper
• Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: a review.

  1999cites this paper
• Studies on calpain expression during differentiation of rat satellite cells in primary cultures in the presence of heparin or a mimic compound.

  1999cites this paper
• Systemic administration of the NF-κB inhibitor curcumin stimulates muscle regeneration after traumatic injury.

  1999cites this paper
• A Single Low Dose of RGTA®, a New Healing Agent, Hastens Wound Maturation and Enhances Bone Deposition in Rat Craniotomy Defects

  1999cites this paper
• Modulation of human endothelial cell proliferation and migration by fucoidan and heparin.

  1998cites this paper
• Antiproliferative polysaccharides modulate distribution and phenotypic expression of collagens by gingival fibroblasts.

  1998cites this paper